JP2016531861A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016531861A5 JP2016531861A5 JP2016516904A JP2016516904A JP2016531861A5 JP 2016531861 A5 JP2016531861 A5 JP 2016531861A5 JP 2016516904 A JP2016516904 A JP 2016516904A JP 2016516904 A JP2016516904 A JP 2016516904A JP 2016531861 A5 JP2016531861 A5 JP 2016531861A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pi3k
- composition
- pharmaceutically acceptable
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 7
- 102000001708 Protein Isoforms Human genes 0.000 claims description 6
- 108010029485 Protein Isoforms Proteins 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims description 5
- 108091007960 PI3Ks Proteins 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 claims description 3
- 101710096503 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000012659 Joint disease Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 2
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims description 2
- 101710093328 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims description 2
- 102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 claims description 2
- 101710125691 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 claims description 2
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 claims description 2
- 101710204747 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 201000003229 acute pancreatitis Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 230000036303 septic shock Effects 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361882473P | 2013-09-25 | 2013-09-25 | |
| US61/882,473 | 2013-09-25 | ||
| PCT/US2014/057499 WO2015048318A1 (en) | 2013-09-25 | 2014-09-25 | A selective inhibitor of phosphatidylinositol 3-kinase-gamma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016531861A JP2016531861A (ja) | 2016-10-13 |
| JP2016531861A5 true JP2016531861A5 (enExample) | 2017-10-05 |
| JP6340416B2 JP6340416B2 (ja) | 2018-06-06 |
Family
ID=51795739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016516904A Expired - Fee Related JP6340416B2 (ja) | 2013-09-25 | 2014-09-25 | ホスファチジルイノシトール３−キナーゼ−ガンマの選択的インヒビター |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10301304B2 (enExample) |
| EP (2) | EP3412668B1 (enExample) |
| JP (1) | JP6340416B2 (enExample) |
| KR (1) | KR20160058950A (enExample) |
| CN (1) | CN105722838B (enExample) |
| AU (1) | AU2014324873B2 (enExample) |
| BR (1) | BR112016006388A2 (enExample) |
| CA (1) | CA2925601C (enExample) |
| CL (1) | CL2016000695A1 (enExample) |
| ES (2) | ES2687593T3 (enExample) |
| IL (1) | IL244742A0 (enExample) |
| MX (1) | MX2016003823A (enExample) |
| RU (2) | RU2018142605A (enExample) |
| SG (2) | SG11201602265PA (enExample) |
| UA (1) | UA117032C2 (enExample) |
| WO (1) | WO2015048318A1 (enExample) |
| ZA (1) | ZA201702252B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| PL3052485T3 (pl) | 2013-10-04 | 2022-02-28 | Infinity Pharmaceuticals, Inc. | Związki heterocykliczne i ich zastosowania |
| CA2943075C (en) | 2014-03-19 | 2023-02-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3313186A4 (en) * | 2015-06-29 | 2019-04-03 | Biomed Valley Discoveries, Inc. | LPT-723 AND IMMUNE CONTROL POINT COMBINATIONS AND TREATMENT PROCEDURES |
| NZ740616A (en) | 2015-09-14 | 2023-05-26 | Infinity Pharmaceuticals Inc | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| CA3015893C (en) * | 2016-03-10 | 2021-11-09 | Astrazeneca Ab | Novel inhibitors of phosphatidylinositol 3-kinase gamma |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| KR102851010B1 (ko) | 2019-04-10 | 2025-08-26 | 난징 젱시앙 파마슈티칼스 컴퍼니 리미티드 | 포스파티딜이노시톨 3-키나제 저해제 |
| JP7665534B2 (ja) | 2019-06-04 | 2025-04-21 | アーカス バイオサイエンシーズ インコーポレイテッド | ２，３，５－三置換ピラゾロ［１，５－ａ］ピリミジン化合物 |
| WO2025228895A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament |
| WO2025228889A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament |
| WO2025228902A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Heterocyclic acids as sting antagonists and the use thereof as medicament |
| WO2025228900A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Arylamide substituted indazoles and the use thereof as medicament |
| WO2025228892A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament |
| WO2025228899A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Further heterocyclic compounds as sting antagonists and the use thereof as medicament |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR071717A1 (es) | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
| UY32582A (es) * | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| AU2010341573B2 (en) * | 2009-12-22 | 2016-10-13 | Vertex Pharmaceuticals Incorporated | Isoindolinone inhibitors of phosphatidylinositol 3-kinase |
-
2014
- 2014-09-25 ES ES14789651.8T patent/ES2687593T3/es active Active
- 2014-09-25 CN CN201480060785.XA patent/CN105722838B/zh not_active Expired - Fee Related
- 2014-09-25 BR BR112016006388A patent/BR112016006388A2/pt not_active Application Discontinuation
- 2014-09-25 ES ES18180366T patent/ES2785053T3/es active Active
- 2014-09-25 UA UAA201604461A patent/UA117032C2/uk unknown
- 2014-09-25 RU RU2018142605A patent/RU2018142605A/ru unknown
- 2014-09-25 JP JP2016516904A patent/JP6340416B2/ja not_active Expired - Fee Related
- 2014-09-25 SG SG11201602265PA patent/SG11201602265PA/en unknown
- 2014-09-25 KR KR1020167010907A patent/KR20160058950A/ko not_active Withdrawn
- 2014-09-25 US US15/024,698 patent/US10301304B2/en active Active
- 2014-09-25 EP EP18180366.9A patent/EP3412668B1/en active Active
- 2014-09-25 MX MX2016003823A patent/MX2016003823A/es unknown
- 2014-09-25 EP EP14789651.8A patent/EP3049415B1/en not_active Not-in-force
- 2014-09-25 SG SG10201802061TA patent/SG10201802061TA/en unknown
- 2014-09-25 WO PCT/US2014/057499 patent/WO2015048318A1/en not_active Ceased
- 2014-09-25 AU AU2014324873A patent/AU2014324873B2/en not_active Ceased
- 2014-09-25 RU RU2016115726A patent/RU2675814C2/ru not_active IP Right Cessation
- 2014-09-25 CA CA2925601A patent/CA2925601C/en active Active
-
2016
- 2016-03-23 IL IL244742A patent/IL244742A0/en unknown
- 2016-03-24 CL CL2016000695A patent/CL2016000695A1/es unknown
-
2017
- 2017-03-30 ZA ZA2017/02252A patent/ZA201702252B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016531861A5 (enExample) | ||
| RU2016115726A (ru) | Селективный ингибитор фосфатидилинозитол-3-киназы-гамма | |
| JP2012521994A5 (enExample) | ||
| JP2015524807A5 (enExample) | ||
| JP2016540749A5 (enExample) | ||
| JP2015514060A5 (enExample) | ||
| EP4275756A3 (en) | Bipyrazole derivatives as jak inhibitors | |
| JP2016516020A5 (enExample) | ||
| BR112015017338A2 (pt) | anticorpos anti-il-17a e seu uso no tratamento de transtornos autoimunes e inflamatórios | |
| MX2008011369A (es) | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2. | |
| MX2019005526A (es) | Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa. | |
| JP2017515819A5 (enExample) | ||
| JP2016507581A5 (enExample) | ||
| JP2013528655A5 (enExample) | ||
| EA201291273A1 (ru) | Ингибиторы киназ, регулирующих апоптозный сигнал | |
| JP2017514910A5 (enExample) | ||
| WO2012048129A3 (en) | Inhibitors of polo-like kinase | |
| WO2014143242A8 (en) | Compounds useful as inhibitors of atr kinase | |
| EA201891143A1 (ru) | Пиперидиноновые агонисты формилпептидного рецептора 2 и формилпептидного рецептора 1 | |
| MX377387B (es) | Nuevo compuesto para usarse en el tratamiento de fibrosis quística. | |
| JP2016509051A5 (enExample) | ||
| JP2017517512A5 (enExample) | ||
| GEP20207098B (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| JP2016028076A5 (enExample) | ||
| JP2016529306A5 (enExample) |